• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

He built a MERS treat­ment in 6 months and then the best Ebo­la drug. Now Chris­tos Kyrat­sous turns his sights on ...

6 years ago
R&D
In Focus

As sick­le cell pa­tients find new op­tions, NEA-found­ed Imara pitch­es mid-stage al­ter­na­tive for $86M IPO

6 years ago
Financing

RA joins glob­al syn­di­cate to back a $98M round for CAN­bridge

6 years ago
Financing
China

Drug dis­cov­ery in HD: Ox­ford spin­of­f's mass spec­trom­e­try ap­proach scores fresh fund­ing

6 years ago
Financing
Startups

Chi­na ap­proves flu drug be­ing tout­ed as a po­ten­tial coro­n­avirus treat­ment amid a rush of clin­i­cal stud­ies

6 years ago
China
Coronavirus

FDA goes on high alert as coro­n­avirus rais­es threat to drug man­u­fac­tur­ing and clin­i­cal tri­als grind to a halt

6 years ago
R&D
FDA+

War­ren Buf­fett gets a dou­ble take as the in­vest­ment pow­er­house set­tles on its first biotech in­vest­ment

6 years ago
R&D

The top 100 bio­phar­ma ven­ture in­vestors at the mega­bil­lions deal ta­ble

6 years ago
Financing

For­mer No­var­tis ex­ec pleads guilty to gener­ic price fix­ing

6 years ago
Pharma

Palleon's first CSO ex­plains how they (and she) got here; En­ter­prise taps Roche and No­var­tis vet David Mor­ris as CMO

6 years ago
Peer Review

New en­tries, price hikes spur changes among the 20 most ex­pen­sive drugs — though not the kind politi­cians like to ...

6 years ago
Pharma

As­traZeneca sweeps two can­cer drugs to the scrap heap; Epizyme nabs pri­or­i­ty re­view for sec­ond rare can­cer NDA

6 years ago
News Briefing

If you were a can­cer pa­tient, where would you rather be — the Unit­ed States or Eu­rope?

6 years ago
R&D

As­traZeneca's Chi­nese in­vest­ment bank part­ner rais­es $229M for its own new fund — and it's all about the ...

6 years ago
R&D
Coronavirus

Coro­n­avirus out­break clouds As­traZeneca's Q4 re­sults and 2020 out­look

6 years ago
R&D
Pharma

The list of the 11 block­busters-to-be in line for a 2020 launch high­light agony and ec­sta­sy of drug R&D

6 years ago
Pharma

In­ter­nal FDA emails re­veal how price, Sanders’ pres­sure played a role in com­peti­tor’s ap­proval, Cat­a­lyst claims

6 years ago
FDA+

Carl June on CRISPR, CAR–T and how the Viet­nam War dropped him in­to med­i­cine

6 years ago
People
R&D

8 years af­ter its OK, Ei­sai yanks its flail­ing obe­si­ty drug from the mar­ket af­ter FDA flagged high­er can­cer rate

6 years ago
Pharma
FDA+

Elan­co grabs $140M in deal with French phar­ma com­pa­ny; An­oth­er com­pa­ny an­nounces a coro­n­avirus vac­cine hunt

6 years ago
News Briefing
Coronavirus

The White House re­view of drug prices: Don't hate the play­er — hate the game

6 years ago
R&D

Seat­tle Ge­net­ics gets an­oth­er drug close to the fin­ish line

6 years ago
R&D

Roche scores its first PD-L1 win in Chi­na, go­ing straight for SCLC niche

6 years ago
China
Pharma

Af­ter FDA hold and tri­al fail­ure, Ipsen writes down its big ac­qui­si­tion — but they're not giv­ing up

6 years ago
Pharma
First page Previous page 857858859860861862863 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times